February 27th, Amsterdam the Netherlands
EvidenceHunt, an AI-powered medical research platform that changes the way professionals pinpoint, analyze, and utilize evidence, has closed a funding round of €1.2m, led by Keen Venture Partners, Dff.ventures and Slimmer AI. The consortium was joined by notable angel investors, including Jeroen Tas (former Chief Strategy and Innovation Officer at Philips), Dinko Valerio (former CEO and Founder Crucell), and James Shannon (former Head of Global Drug Development Novartis).
EvidenceHunt launched its platform 1.5 years ago following two years of research and scientific validation of its core components. Since then, it has grown organically to a global userbase of 25,000 active and returning users, including healthcare professionals, medical science experts, researchers and students across 90+ countries.
Searching for medical evidence is a time-consuming and frustrating process. Nowadays professionals spend countless hours creating complex queries, and sifting through PubMed, Guidelines, and Protocols to find reliable answers. This inefficiency costs valuable time and utlimately slows down evidence-based decision-making.
With EvidenceHunt, everything changes. Users can now ask questions and receive clear, summarized answers within seconds – complete with cited sources and trackable details for instant verification of how the AI has generated its answers. For example, where orienting oneself within existing scientific literature once required hours of manually reviewing and filtering publications, this process can now be completed in a matter of seconds. Similarly, zooming in on specific topics and extracting precise data from vast amounts of literature – like finding a needle in a haystack – can now be done just as quickly. As a result, literature reviews, which previously took several days or even weeks, can now be completed in a matter of hours. Depending on their profession and use cases, users have reported saving up to 5 hours per week.
“As a medical doctor and PhD, I know firsthand how frustrating it can be to spend countless hours navigating PubMed, guidelines, and protocols. From day one, we built EvidenceHunt to mimic domain-specific logic and processes for evaluating and interpreting literature. But we aim to do more than just save time – we provide clear answers that users can trace back to credible sources. Unlike generic AI platforms, our goal with EvidenceHunt is not to be a black box; it’s designed to empower users with transparency and reliability, which are essential for adoption and for earning the trust of the medical community,” said Philippe Habets, CEO of EvidenceHunt.
EvidenceHunt is using the funding to extend the platform’s capabilities, enabling teams and organizations to efficiently process medical information. Teams will have full control over the input, deciding what type of data they integrate, such as protocols, guidelines, unpublished research, or any other internal document. At the same time, they gain control over the output. Instead of just receiving summaries, they can build structured dossiers, documentation, or templates directly within EvidenceHunt. Additionally, the platform offers advanced collaboration features, allowing healthcare and pharmaceutical professionals to find and share relevant information more quickly and effectively. Following a successful launch, EvidenceHunt has already onboarded its first enterprise customers, including healthcare institutions and pharmaceutical companies.
Investor JC Heyneke from Slimmer AI, and former GM at Elsevier, stated: “EvidenceHunt addresses a clear pain point for users across various segments worldwide. By integrating into institutional workflows and with institutional data, and applying the latest LLM technology in a powerful vertical-AI SaaS solution, EvidenceHunt taps into a large and growing market”.
About EvidenceHunt
EvidenceHunt was founded by medical doctors, scientists, and data science experts to transform how medical evidence is gathered, analyzed, and applied – enabling faster, evidence-based decision-making. Today, it supports a growing global user base across diverse sectors, including pharmaceutical and medical device companies, healthcare providers and academic institutions.
About Keen Venture Partners
Keen Venture Partners is a radically human venture capital firm based in Amsterdam and London. Keen backs exceptional teams and fast-growing European tech companies from seed to Series B. Keen invests through a thesis-driven approach, formulating investment ideas based on fundamental trends in specific areas of technology. When getting to know founders, Keen shares its network of operators, experience, and capabilities even before investing. The portfolio consists of 30+ startups and scaleups across Europe. You can find more information at: www.keenventurepartners.com
About Keen Venture Partners
Keen Venture Partners is a radically human venture capital firm based in Amsterdam and London. Keen backs exceptional teams and fast-growing European tech companies from seed to Series B. Keen invests through a thesis-driven approach, formulating investment ideas based on fundamental trends in specific areas of technology. When getting to know founders, Keen shares its network of operators, experience, and capabilities even before investing. The portfolio consists of 30+ startups and scaleups across Europe. You can find more information at: www.keenventurepartners.com
Contact
For media inquiries, please contact: Olivier Magnin COO EvidenceHunt Email: olivier@evidencehunt.com Website: www.evidencehunt.com
7 March 2025 to 8 March 2026 'Unseen' reveals how, for centuries, medical science has taken the male body as the norm, often overlooking women and gender-diverse individuals....
Leiden researchers have made a groundbreaking discovery in understanding type 1 diabetes (T1D). Led by Professor Bart Roep, LUMC researchers have identified how genetic...
Last night, Leiden Bio Science Park looked a little different. With colored lights in hand, we set out to illuminate the park—bringing visibility to the 300 million people...